Publication:
Comparison of methotrexate and Azathioprine as the first steroid-sparing immunosuppressive agent in patients with Takayasu's Arteritis

dc.contributor.coauthorKaymaz-Tahra, Sema
dc.contributor.coauthorTsechelidis, Ozun Bayindir
dc.contributor.coauthorInce, Burak
dc.contributor.coauthorIsik, Ozlem Ozdemir
dc.contributor.coauthorKutu, Muhammet Emin
dc.contributor.coauthorKarakas, Ozlem
dc.contributor.coauthorYildirim, Tuba Demirci
dc.contributor.coauthorAdemoglu, Zeliha
dc.contributor.coauthorEdiboglu, Elif Durak
dc.contributor.coauthorUludogan, Burcu Ceren Ekti
dc.contributor.coauthorIlgin, Can
dc.contributor.coauthorBilge, Sule Yasar
dc.contributor.coauthorKasifoglu, Timucin
dc.contributor.coauthorAkar, Servet
dc.contributor.coauthorEmmungil, Hakan
dc.contributor.coauthorOnen, Fatos
dc.contributor.coauthorOmma, Ahmet
dc.contributor.coauthorYazici, Ayten
dc.contributor.coauthorCefle, Ayse
dc.contributor.coauthorInanc, Murat
dc.contributor.coauthorAksu, Kenan
dc.contributor.coauthorKeser, Gokhan
dc.contributor.coauthorDireskeneli, Haner
dc.contributor.coauthorAlibaz-Oner, Fatma
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorKanıtez, Nilüfer Alpay
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-03-06T20:57:29Z
dc.date.issued2023
dc.description.abstractBackground Conventional disease-modifying anti-rheumatic drugs (cDMARDs) are recommended in addition to glucocorticoids (GC) for all active Takayasu's arteritis (TAK) patients as the first-line therapy.However, there is limited data comparing cDMARDs as the first-line immunosuppressive (IS) treatment. Objectives In this study, we aimed to compare the outcomes of methotrexate (MTX) and azathioprine (AZA), which were used most frequently as the first-line cDMARDs in TAK patients.
dc.description.indexedbyWOS
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.eissn2326-5205
dc.identifier.issn2326-5191
dc.identifier.quartileQ1
dc.identifier.urihttps://hdl.handle.net/20.500.14288/27252
dc.identifier.volume75
dc.identifier.wos1190014303066
dc.keywordsTakayasu’s arteritis
dc.keywordsBiologic immunosuppressive treatment
dc.keywordsPatient characteristics
dc.keywordsFollow-up
dc.keywordsDaily practice
dc.keywordsBiologic therapy
dc.keywordsTreatment selection
dc.keywordsArteritis management
dc.keywordsImmunosuppressive therapy
dc.keywordsChronic disease management
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofARTHRITIS and RHEUMATOLOGY
dc.subjectRheumatology
dc.titleComparison of methotrexate and Azathioprine as the first steroid-sparing immunosuppressive agent in patients with Takayasu's Arteritis
dc.typeOther
dc.type.otherMeeting abstract
dspace.entity.typePublication
local.contributor.kuauthorKanıtez, Nilüfer Alpay
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files